CompletedNot Applicable

577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy

China68 participantsStarted 2016-09

Plain-language summary

The purpose of this study is to determine whether micropulse laser (MPL) is different to half-dose photodynamic therapy on acute central serous chorioretinopathy.

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. onset for the first time, as an episode duration of less than 6 months
✓. patient was between 18 and 55 years of age
✓. the presence of subretinal fluid(SRF) involving the macula and detected by use of optical coherence tomography (OCT)
✓. active fluorescein leakage during fluorescein angiography (FA)
✓. best corrected visual acuity (BCVA) more than 0.1, and less than 1.0

Exclusion criteria

✕. previous PDT, focal photocoagulation, intravitreal injections of anti-vascular endothelial growth factor, or ocular surgery
✕. other macular abnormalities such as choroidal neovascularization(CNV) or polypoidal choroidal vasculopathy(PCV)
✕. retinal atrophy
✕. pregnancy
✕. inability to obtain photographs or to perform FA
✕. use of steroid systemically or topically in the last 6 months

What they're measuring

the proportion of eyes with complete absorption of subretinal fluid(SRF)

Timeframe: 1 month

Trial details

NCT IDNCT02587767

SponsorSun Yat-sen University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12

View on ClinicalTrials.gov More Acute Central Serous Chorioretinopathy trials